Business Context and Reporting Period
This Form 8-K Current Report was filed by Cara Therapeutics, Inc. (not Tvardi Therapeutics, Inc.) on October 1, 2020. The filing reports the appointment of a new Chief Financial Officer and related compensatory arrangements.
Key Financial Metrics
This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation details:
- Base Salary: $400,000 annually.
- Signing Bonus: $30,000 (clawback provisions apply if terminated prior to the first anniversary).
- Target Bonus: 40% of annual base salary.
- Equity Grant: Option to purchase 175,000 shares of common stock, vesting over four years (25% on the first anniversary, remainder monthly).
Material Changes
The primary material change reported is the appointment of Thomas Reilly as Chief Financial Officer, effective October 1, 2020. Mr. Reilly joins from Allergan plc (AbbVie), where he served as Head of Finance for U.S. Pharma General Medicines. He brings over 20 years of experience in biopharmaceutical financial operations.
Outlook, Risks, and Contingencies
Employment Terms and Severance:
- Employment is "at-will."
- Termination without cause (after 1 year): Entitles the executive to nine months of base salary, 50% of the target bonus (pro-rated), and nine months of COBRA premiums.
- Termination without cause (before 1 year): Entitles the executive to three months of base salary and three months of COBRA premiums.
- Change in Control: Unvested equity awards vest in full if terminated without cause within three months prior to or 12 months after a change in control.
Risks: The filing notes that the summary of compensatory arrangements is qualified by reference to the full employment agreement filed as Exhibit 10.1.
Investor Verification Checklist
- Verify the exact vesting schedule and exercise price of the 175,000 stock options granted to Thomas Reilly.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "termination without cause" and "change in control."
- Confirm the impact of this executive appointment on the company's cash burn rate, given the new salary and bonus obligations.
- Check for any subsequent filings regarding the departure of the previous CFO, if applicable.